Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark.
Breast. 2012 Aug;21(4):556-61. doi: 10.1016/j.breast.2012.05.003. Epub 2012 Jun 4.
The aim was to evaluate activity and toxicity of hepatic arterial infusion of oxaliplatin in combination with capecitabine in patients with metastatic breast cancer with liver metastases and limited extrahepatic disease.
Sixteen consecutive patients received capecitabine 13 00mg/m(2) daily combined with oxaliplatin 85 mg/m(2) every two weeks. Seven patients alternated between intrahepatic and systemic oxaliplatin, and in 9 oxaliplatin was primarily given intrahepatic. Five patients had liver-only metastases and 11 had additionally bone metastases. The patients had received median two previous chemotherapeutic regimens for metastatic disease.
The response rate was 50% and the stable disease (≥6 months) rate 44%. Median progression free and overall survival was 7.9 and 19.2 months, respectively. The toxicity was moderate with abdominal pain, neuropathy, and hand foot syndrome as the most common adverse events.
The combination of capecitabine and intrahepatic/systemic therapy with oxaliplatin was active in pretreated patients with liver metastasis from breast cancer.
目的在于评估转移性乳腺癌伴肝转移和有限的肝外疾病患者中，肝动脉输注奥沙利铂联合卡培他滨的活性和毒性。
16 例连续患者接受卡培他滨 1300mg/m²，每日一次，联合奥沙利铂 85mg/m²，每两周一次。7 例患者在肝内和全身奥沙利铂之间交替使用，9 例奥沙利铂主要用于肝内。5 例患者仅存在肝转移，11 例患者另外存在骨转移。这些患者在转移性疾病中已经接受了中位数为两种的化疗方案。
反应率为 50%，稳定疾病（≥6 个月）率为 44%。无进展生存期和总生存期的中位数分别为 7.9 和 19.2 个月。毒性为中度，最常见的不良反应为腹痛、神经病变和手足综合征。
卡培他滨联合肝内/全身奥沙利铂治疗方案对转移性乳腺癌伴肝转移的患者具有活性。
